Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Sponsor
Emory University
Study ID
NCT00636298
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab, cetuximab — DRUG
    Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly Bevacizumab - 10 mg/kg every 2 weeks

Study Details

The purpose of this study is to test the drug bevacizumab in combination with cetuximab. Because this combination has not been tested in cancer patients before, results will be analyzed to see what effects the combination of bevacizumab with cetuximab has on esophageal cancer.

Key Dates

First listed
Mar 14, 2008
Start date
Oct 31, 2008
Status verified
Nov 2013
Primary completion
Mar 31, 2010
Completion
Mar 31, 2012

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A
    Single arm treatment with combination of cetuximab and bevacizumab

Primary Outcome Measure

Progression-free survival [ Time Frame: Every 3 months ]

Related Studies